BioSpace News Archive

The industry of the high content screening market is growing with venture capital investments and rising funding for cellular research.

Everest Medicines announced that the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China has approved the investigational new drug application under Class One category for SPR206, a novel, intravenous next-generation polymyxin product candidate in development for the treatment of multi-drug resistant gram-negative bacterial infections.

Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announce that the European Patent Office has granted EU Patent no EP3402889.

AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, announced positive high-level results from the PROpel Phase III trial.

Celldex Therapeutics, Inc. announced that senior management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 1:20 p.m. ET.

A computer program trained to see patterns among thousands of breast ultrasound images can aid physicians in accurately diagnosing breast cancer, a new study shows.

SAB Biotherapeutics announced that an independent Data Safety Monitoring Board has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended advancement to Phase 3.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2021 operating results on Wednesday, September 29, 2021

Join the Company on Wednesday October 27th at 8:30am ET to hear about its AI vision and how it can enhance its deep technology

PetVivo Holdings, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.